Tallinn University of Technology-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2016

  1. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: Rationale for further study on blood pressure targets of antihypertensive treatment after stroke

    Journal of Hypertension, Vol. 34, Núm. 3, pp. 393-396

  2. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia

    European Heart Journal, Supplement, Vol. 18, pp. C2-C12

2015

  1. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy

    Atherosclerosis Supplements, Vol. 19, pp. 1-12

2014

  1. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: Design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial

    Journal of Hypertension, Vol. 32, Núm. 9, pp. 1888-1897

  2. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: A review of available trial evidence

    Journal of Hypertension, Vol. 32, Núm. 9, pp. 1741-1750

2013

  1. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

    European Heart Journal, Vol. 34, Núm. 28, pp. 2159-2219

  2. Identification of the hemodynamic modulators and hemodynamic status in uncontrolled hypertensive patients

    Blood Pressure, Vol. 22, Núm. 6, pp. 362-370